# A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period

Study · id `cardio:ct-nct05002933` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05002933](<https://clinicaltrials.gov/study/NCT05002933>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05002933

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 570 participants.

## Technical summary

Registry record NCT05002933. Allocation not applicable; no masking; primary purpose treatment. Start 2021-05-20 (actual); primary completion 2023-02-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 570 participants (enrolled count; ClinicalTrials.gov record NCT05002933, source copy `cardio:ctgov-nct05002933-2025-09-22`, retrieved 2026-10-26)
- Started: 2021-05-20 (actual) (ClinicalTrials.gov record NCT05002933, source copy `cardio:ctgov-nct05002933-2025-09-22`, retrieved 2026-10-26)
- Primary completion: 2023-02-24 (actual) (ClinicalTrials.gov record NCT05002933, source copy `cardio:ctgov-nct05002933-2025-09-22`, retrieved 2026-10-26)
- Completion: 2023-02-24 (actual) (ClinicalTrials.gov record NCT05002933, source copy `cardio:ctgov-nct05002933-2025-09-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05002933, source copy `cardio:ctgov-nct05002933-2025-09-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05002933-2025-09-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period
- Acronym: INITIATION
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin glargine 300 U/ml
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study (`cardio:pubmed-39075925`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 40a0ec79aab162c508eaacc839aa7bc2a5529d964685d11ab985488d56d8511a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
